No Data
No Data
Ascentage Pharma to Present Four Studies at US Oncology Meet
Ascentage Pharma Group International (HKG:6855) will present data from four studies at an oncology meeting in the US from May 31 to June 4, according to a Thursday filing with the Hong Kong bourse. Th
Yasheng Pharmaceutical-B (06855): Four studies were selected for the ASCO Annual Meeting, and the latest progress of Nellick's treatment of SDH-deficient GIST was presented orally
Zhitong Finance App News, Yasheng Pharmaceutical-B (06855) issued an announcement. Four clinical studies of the company's three key varieties were selected for the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, and one of them received an oral report. These three key varieties are the first and only third-generation BCR-ABL inhibitor approved for marketing in China, olebatinib (HQP1351; trade name: Nelick), the Bcl-2 selective inhibitor APG-2575, and the FAK/ALK/ROS1 triple inhibitor APG-2449. The annual ASCO annual conference is the field of global oncology
亞盛醫藥-B:2023年報
Ascentage Pharma Chairman Boosts Stake in Firm
Ascentage Pharma Group International (HKG:6855) Chairman Yang Dajun acquired an additional 80,000 ordinary shares in the company for approximately HK$1.4 million or HK$17.08 apiece. According to the f
Some Hong Kong biotech stocks rose higher, and Cansino Biotech rose more than 10%
Glonghui, April 9 | Cansino Biotech rose more than 10%, Yiming Anke rose more than 9%, and Yasheng Pharmaceutical rose more than 6%.
Yasheng Pharmaceutical-B (06855.HK) was increased by 80,000 shares of the company by Executive Director and Chairman Yang Dajun
Yasheng Pharmaceutical-B (06855.HK) announced that the company was informed by Yang Dajun, the company's executive director and chairman of the board of directors, that on April 5, 2024 and April 8, 2024, he subscribed for a total of 80,000 shares of the company's common shares. The total cost was about HK$1,3662 million. The average price was about HK$17.08 per share, accounting for about 0.028% of the company's total issued share capital on the date of this announcement.
No Data